From A Very Different Angle: Crocs, Inc. (CROX), Zynerba Pharmaceuticals, Inc. (ZYNE)

Paterniano Del Favero
Agosto 9, 2017

(NASDAQ:ZYNE)'s ATR is 1.73.

Since the beginning of the calendar year, Zynerba Pharmaceuticals, Inc. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain.

Zynerba Pharmaceuticals (ZYNE) traded up 33.0813% during midday trading on Tuesday, reaching $8.3442.

Several equities research analysts recently weighed in on ZYNE shares.

Let's talk about the gap between analyst price targets for the next 12 months and Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its earnings results on Tuesday, August 1st. Finally, Zacks Investment Research upgraded shares of Zynerba Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, July 13th. Roth Capital set a $30.00 price objective on Zynerba Pharmaceuticals and gave the stock a "buy" rating in a research report on Saturday, June 10th. The company has an average rating of "Hold" and a consensus price target of $20.11.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) opened at 6.27 on Wednesday. The company has market cap of $83.12 million. The Company has 52-week high of $25.95 and 52-week low of $5.93. (ZYNE)'s latest closing price distance was at -65.08% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at -64.24% and -62.43% compared with the 20 Day Moving Average. Zynerba Pharmaceuticals also was the recipient of unusually large options trading activity on Monday. Stock traders acquired 7,953 put options on the stock. The company reported ($0.64) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.60) by $0.04. On average, equities analysts predict that Zynerba Pharmaceuticals will post ($2.46) EPS for the current year.

TRADEMARK VIOLATION WARNING: "Bank of New York Mellon Corp Boosts Stake in Zynerba Pharmaceuticals, Inc". (NASDAQ:ZYNE), we notice that the stock is -55.60% off of the 20-Day Simple Moving Average. If you are viewing this piece on another website, it was stolen and reposted in violation of U.S. and worldwide trademark and copyright legislation. The legal version of this piece of content can be read at

In other news, CFO James E. Fickenscher purchased 5,200 shares of the stock in a transaction dated Friday, May 12th. The stock was acquired at an average cost of $19.82 per share, for a total transaction of $103,064.00. Following the completion of the transaction, the chief financial officer now owns 12,200 shares of the company's stock, valued at approximately $241,804. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Armando Anido bought 5,000 shares of the firm's stock in a transaction on Monday, May 15th. Following the purchase, the chairman now owns 336,012 shares of the company's stock, valued at $6,619,436.40. The disclosure for this purchase can be found here. Foot Locker, Inc. has 10 buy ratings, 9 holds and 0 sells even after the stock tumbled -37% from its high of $79.43 to a $6.58 billion market value through last close.

A number of institutional investors have recently modified their holdings of ZYNE. FNY Managed Accounts LLC purchased a new stake in shares of Zynerba Pharmaceuticals during the first quarter worth about $180,000.

Bank of New York Mellon Corp raised its stake in Zynerba Pharmaceuticals, Inc. Marshall Wace North America L.P. acquired a new position in shares of Zynerba Pharmaceuticals during the first quarter worth about $9,362,000.

Altre relazioni OverNewsmagazine

Discuti questo articolo